Inicio / De Interés / Artículos Científicos (page 5)

Artículos Científicos

Nickel contact dermatitis in children

lin Dermatol. 2015 May-Jun;33(3):320-6. doi: 10.1016/j.clindermatol.2014.12.008. Epub 2014 Dec 8. Nickel contact dermatitis in children. Tuchman M1, Silverberg JI2, Jacob SE3, Silverberg N4. Author information Abstract Nickel is the most commonly detected cutaneous allergen on patch testing in the United States for children. The ubiquitous nature of nickel as a …

Ampliar »

Nickel hypersensitivity and orthodontic treatment: a systematic review and meta-analysis

Contact Dermatitis. 2015 Jul;73(1):1-14. doi: 10.1111/cod.12392. Epub 2015 Apr 16. Nickel hypersensitivity and orthodontic treatment: a systematic review and meta-analysis. Gölz L1, Papageorgiou SN1,2, Jäger A1. Author information Abstract Nickel-containing alloys are widely used in orthodontic appliances, even though nickel is by far the most common contact allergen. However, the …

Ampliar »

Recent advances of pharmacogenomics in severe cutaneous adverse reactions: immune and nonimmune mechanisms.

Dao RL1, Su SC1, Chung WH1. Abstract Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and drug reaction with eosinophilia and systemic symptoms (DRESS) are severe cutaneous adverse reactions (SCAR) which are majorly caused by drugs. Though the incidence rate is low, SCAR sometimes can be life-threatening and leads to lifelong …

Ampliar »

Anti-Amoxicillin Immunoglobulin E, Histamine-2 Receptor Antagonist Therapy and Mast Cell Activation Syndrome Are Risk Factors for Amoxicillin Anaphylaxis

Pastorello EA1, Stafylaraki C, Mirone C, Preziosi D, Aversano MG, Mascheri A, Losappio LM, Ortolani V, Nichelatti M, Farioli L. Abstract BACKGROUND: ?-Lactam antibiotics (mainly amoxicillin, AX) are the drugs that most frequently induce systemic drug allergy reactions. OBJECTIVE: We attempted to identify the risk factors associated with systemic reactions …

Ampliar »

Epidemiology of Adverse Cutaneous Drug Reactions. A Prospective

Study in Hospitalized Patients Amparo Herna´ndez-Salazar,a Samuel Ponce-de-Leo´n Rosales,b Sigfrido Rangel-Frausto,b Elia Criollo,c Carla Archer-Dubon,a and Roc?´o Orozco-Topetea aDermatology Department, bSubdivision of Hospital Epidemiology and Patient Care Quality Control, cPharmacy Department, Instituto Nacional de Ciencias Médicas y Nutrición, Salvador Zubira´n, Mexico City, Mexico Received for publication June 2, 2005; accepted …

Ampliar »

Guia del manejo del Penfigoide ampollar

Feliciani,1 P. et al Management of bullous pemphigoid: the European Dermatology Forum consensus in collaboration with the European Academy of Dermatology and Venereology British Journal of Dermatology (2015) 172, pp867–877 Bullous pemphigoid is the most common autoimmune subepidermal blistering disease of the skin and mucous membranes. This disease typically affects …

Ampliar »

¿Cuál es la eficacia de la terapia fotodinámica, en comparación con la crioterapia, como tratamiento de las lesiones de queratosis actínica?

Patel G, Armstrong AW, Eisen DB. Efficacy of photodynamic therapy versus other interventions in randomized clinical trials for the treatment of actinic keratoses. A systematic review and meta-analysis. JAMA Dermatol. 2015; 150(12): 1281-8. Las terapias fotodinámicas constituyen un Tratamiento habitual contra las distintas formas de queratosis actínica. La presente Revisión tiene por objeto examinar …

Ampliar »

La exposición a la isotretinoína incrementa el riesgo de sufrir enfermedad inflamatoria intestinal?

Rashtak S, Khaloghi S, Pittolkow MR y colaboradores Isotretinoin exposure and risk of inflammatory bowel disease.JAMA Dermatol. 2014; 150(12): 1322-6. La isotretinoína (ácido 13-cis-retinoico) es un fármaco que resulta muy efectivo contra los acnés de grado 4, los más severos de todos, y en especial contra el acné noduloquístico refractario. …

Ampliar »

Artículo de interes sobre fiebre chikungunya

Cortesia de Juan Chassaigne Reciba un cordial saludo, a través de la presente le enviamos artículo sobre Fiebre Chikungunya, cortesía del grupo de trabajo de Epidemiología, Prevención y Salud Pública de la Sociedad Venezolana de Infectología. Atentamente, POR LA JUNTA DIRECTIVA Dra. Elia Sánchez Presidenta SVI _______________ Archivos Adjuntos: NEJMchikungunyaMarzo26.pdf …

Ampliar »

Efficacy and safety of diphenylcyclopropenone alone or in combination with anthralin in the treatment of chronic extensive alopecia areata: A retrospective case series

Durdu M1, Özcan D2, Baba M3, Seçkin D2. Author information Abstract BACKGROUND: Some patients with chronic extensive alopecia areata (AA) may be refractory to topical immunotherapy. Combination therapy is recommended for such patients. Efficacy and safety of a combination therapy with diphenylcyclopropenone (DPCP) and anthralin in chronic extensive AA is …

Ampliar »

Treatment of alopecia areata with topical sensitizers

Sutherland L1, Laschinger M, Syed ZU, Gaspari A. Author information Abstract For those with severe alopecia areata, with greater than 50% scalp involvement, topical immunotherapy with diphenylcyclopropenone or squaric acid dibutylester is considered the treatment of choice. This article not only reviews the safety and efficacy of topical sensitizers for …

Ampliar »

Intravenous methylprednisolone pulse therapy in severe alopecia areata

Senila SC, Danescu SA, Ungureanu L, Candrea E, Cosgarea RM1. Author information Abstract BACKGROUND: Severe, extensive, therapy resistant alopecia areata represents a clinical challenge. Systemic corticosteroids are a therapeutic tool that still needs to be evaluated. AIM: The purpose of this study was to assess the efficacy and safety of …

Ampliar »

Alopecia Universalis Successfully Treated With Adalimumab

Gorcey L1, Spratt EA1, Leger MC1. Author information Abstract Importance: Alopecia universalis is an uncommon form of alopecia areata (AA) involving hair loss over the entire scalp and body and is often difficult to treat. Tumor necrosis factor (TNF) inhibitors have been largely unsuccessful in treating AA and have been …

Ampliar »

Este sitio web utiliza cookies para que usted tenga la mejor experiencia de usuario. Si continúa navegando está dando su consentimiento para la aceptación de las mencionadas cookies y la aceptación de nuestra política de cookies, pinche el enlace para mayor información.plugin cookies

ACEPTAR
Aviso de cookies